Articles tagged with Prostate Cancer
Researchers at the University of South Australia have developed a novel formulation of the prostate cancer drug abiraterone acetate, improving its effectiveness by 40%. The new oral formulation reduces side effects and allows for a smaller dose to be effective without fasting.
Key recommendations from the Philadelphia Prostate Cancer Consensus Conference include performing genetic testing for all men with metastatic prostate cancer and those with a family history of hereditary cancers. Recommended genes for testing include BRCA2, BRCA1, and DNA mismatch repair genes. Genetic testing is also recommended to in...
Researchers have identified a variant in the genome associated with higher risk of prostate cancer in African American men. This variant is found in about 12% of men of African ancestry and increases their risk two-fold.
Researchers identified four subtypes of prostate cancer with distinct characteristics, affecting treatment strategies and potentially improving patient outcomes. The study's findings suggest that one subtype requires intensified treatments while another is less aggressive, paving the way for more targeted therapies.
A UK-first pilot study has shown that genetic screening for prostate cancer can safely identify undiagnosed cases in approximately one-third of otherwise healthy men. The study involved testing for 130 DNA changes and found that population screening was effective at detecting new cancers in this high-risk group.
A new test developed by researchers at the University of Birmingham uses complex sugars to detect prostate cancer earlier and with greater accuracy. The test identifies glycans in blood that are associated with different cancers, allowing for more precise diagnoses.
Olaparib, a PARP inhibitor, targets genetic mutations in advanced prostate cancer patients with BRCA1 and BRCA2. The FDA approved the drug for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.
A new mathematical model predicts prostate cancer tumor growth and invasiveness based on stromal ecology, revealing that highly reactive stroma drives aggressive tumors. The model was validated in animal models and patients, suggesting improved prognosis with ecological metrics.
Researchers have found that the new radiotracer 18F-PSMA-1007 offers advantages over established agent 68Ga-PSMA-11 in staging prostate cancer. The study showed near-equal performance between the two tracers, with 18F-PSMA-1007 detecting additional lesions in four patients.
A study of 4532 men found that those on androgen-deprivation therapies had a four-fold reduced risk of COVID-19 infections compared to those not on ADT. The researchers suggest that even non-prostate cancer patients at high risk could take ADT for prevention.
Researchers at Memorial Sloan Kettering Cancer Center discovered that nearly all cells in the prostate gland contribute to its regrowth after androgen-deprivation therapy. Luminal cells acquire stem-like properties without hormone influence, leading to implications for prostate cancer treatment and potential therapeutic strategies.
A clinical trial has identified a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment. The study found that these tumors had lower androgen receptor activity and higher stemness, making them more adaptable and resistant to treatment.
The NCCN Guidelines for Patients are among the most trustworthy resources for patients and caregivers seeking information on prostate cancer. The guidelines, written in an easy-to-learn format, provide essential information on diagnosis and treatment.
Researchers developed a mathematical model that forecasts patient responses to intermittent androgen deprivation therapy based on changing levels of the biomarker PSA. The model predicted 89% accuracy in developing patient resistance, enabling personalized treatment options.
A Phase II trial found patients with metastatic castration-resistant prostate cancer who showed active T-cell responses in their tumors experienced prolonged survival after ipilimumab treatment. Researchers identified biomarkers associated with improved responses, including higher T-cell density and interferon-γ signaling.
A recent study analyzing nearly 230,000 men found significant racial disparities in prostate cancer survival rates across the United States. The research identified geographic areas with lower survival rates for certain racial groups compared to white patients.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
A randomized trial of high-dose targeted radiation versus observation found no significant difference in progression prevention among 54 men with recurrent hormone-sensitive prostate cancer. The study suggests that observation may be a viable alternative to radiation therapy for this patient population.
Researchers found that overexpression of hPCL3S promotes proliferation, anchorage-independent growth, and migration in human LNCaP prostate cancer cells. Silencing of endogenous hPCL3S in DU145 and PC3 prostate cancer cells impairs these effects.
Researchers analyzed DNA haplotypes associated with hereditary prostate cancer (HPC) and found that one mutation increased risk by 22-fold. The study identified 183 variants linked to HPC at genome-wide significance, shedding light on the genetic factors contributing to disease.
A new molecular imaging technique, PSMA PET/CT, is more accurate than conventional medical imaging in detecting prostate cancer spread. The approach helps doctors tailor treatments by identifying disease extent at diagnosis.
The study discovered a link between the amount of DESNT subtype cells in a tumor sample and disease progression. The findings also identified three new subtypes of prostate cancer that could be used to stratify patients for different treatments.
Researchers found African-American men are less likely to use a more targeted biopsy option for prostate cancer, which could lead to overdiagnosis and underdiagnosis of the disease. The study suggests that socioeconomic or cultural biases may be influencing this disparity.
A study led by James Cook University found that supervised exercise sessions can reduce the negative side effects of Androgen Deprivation Therapy (ADT) in prostate cancer patients. The research showed sustained benefits in cardiovascular risk profile and quality of life, but not in cardiopulmonary fitness and fatigue.
Researchers developed a microfluidics device that isolates cancer cells from urine, achieving high detection rates of up to 85% and 86% for localized cancer cases. The new method provides an alternative to invasive tissue biopsies and blood tests with false positive results.
Researchers at UCL have developed a new test to identify the earliest genetic changes of prostate cancer in blood plasma. The process, known as DNA methylation, uses Next Generation Sequencing (NGS) to establish if prostate cancer DNA is present in blood plasma.
Researchers have developed a new method to identify biomarkers for prostate cancer in urine samples, which can help reduce unnecessary biopsies. The test combines multiple components of urine and uses machine learning techniques to accurately predict disease status without invasive biopsy.
Researchers used AI to analyze digitized images of cancer tissues and found critical variations between black and white male patients, which could improve care for black patients with prostate cancer. The study suggests that there are biological differences in the disease that cannot be explained by other disparities.
A recent study published in Annals of Oncology found that excess body fat in middle to late adulthood increases the risk of developing advanced prostate cancer. Maintaining a healthy weight through healthy eating and exercise can help reduce this risk.
A combination of MRI and traditional biopsies significantly detects aggressive prostate cancers than standard biopsy alone. This method enables better diagnosis and reduces unnecessary treatment for slow-growing cancers.
A pilot study at USC found that an MAO inhibitor called phenelzine can help patients with recurrent prostate cancer by disrupting tumor growth pathways. The drug has fewer side effects compared to standard hormone therapy treatments.
Researchers at Johns Hopkins Medicine developed a proof-of-principle urine test detecting prostate cancer using RNA and metabolites in the urine. The test identified cancer-specific changes in urinary RNAs and metabolites that may lead to future development of a noninvasive diagnostic tool.
A new study suggests that lengthening the time between prostate cancer screenings can significantly reduce overdiagnosis and improve outcomes. The research found that discontinuing screening at age 60 would greatly reduce overdiagnoses by 79-82%, but save fewer lives compared to screening until age 69.
A new study identifies a strong cancer driver gene linked to alternative splicing changes in aggressive cancers. The researchers developed computational tools and biological model systems to analyze RNA sequences from nearly 900 prostate tissue samples, revealing over 13,000 alternative splicing events.
Researchers found a genetic variant associated with aggressive disease and shorter survival in men with metastatic prostate cancer. Genetic testing for the HSD3B1(1245C) variant may help identify patients most likely to benefit from additional treatment.
A new study published in The Journal of Urology found that most patients who underwent prostate cancer surgery experienced low levels of decision regret. Patients who played a more active role in treatment decision-making were less likely to experience regret about their choices, regardless of whether they opted for robot-assisted or o...
Research found that statins, alone or with metformin, increase survival in men with high-risk prostate cancer. Metformin plus statin was associated with a 36% reduction in risk of death compared to non-users, while statins alone showed a 54% reduction in PCA mortality among patients with high-risk prostate cancer.
Researchers identified novel PMEPA1-e isoform and characterized its biological functions in prostate cancer. The study found that the methylation of PMEPA1 gene promoter accounts for silencing of PMEPA1 in prostate cancer cells.
Researchers analyzed DNA data from African American and Caucasian American men with prostate cancer, finding lower frequencies of pathogenic/likely alterations in 14 well-characterized DNA repair genes among African Americans. The study suggests a higher risk for germline BRCA mutations but lower risks for non-BRCA mutations
A new approach inhibiting FABP5 may halt disease progression in metastatic prostate cancer. Researchers developed novel FABP5 inhibitors exhibiting significant cytotoxicity against highly drug-resistant cells.
In an equal-access health care system, African American men with prostate cancer did not have more advanced disease at diagnosis or die earlier than white men. Access to high-quality medical care may help address racial disparities in prostate cancer outcomes.
A five-year follow-up study of over 2,000 U.S. men with localized prostate cancer found that radiation therapy was associated with significant declines in erectile function, while surgery improved function over time. Prostatectomy also resulted in worse urinary incontinence compared to other treatments.
A randomized clinical trial found that a telephone-based program encouraging increased vegetable consumption did not decrease the risk of prostate cancer progression over two years. The study suggested that the intervention may have been underpowered to identify a clinically important difference in cancer progression.
A Phase III clinical trial found that eating seven or more servings of vegetables and fruits daily did not provide extra protection against prostate cancer. Despite this, a healthy diet rich in fruits and vegetables may help patients tolerate cancer treatments.
Researchers at Radboud University Medical Center developed an AI system that accurately diagnoses prostate cancer aggressiveness using deep learning. The system performed better than ten human pathologists and provided consistent results, reducing the need for subjective Gleason scoring.
In 2020, prostate cancer will claim the most diagnoses among male cancers, with a 21% share of new cases. Early detection is crucial, but screening's benefits are disputed by some, leading to fewer men taking proactive steps towards their health.
Researchers developed an AI system that can detect and grade prostate cancer with accuracy comparable to world-leading uro-pathologists. The system has the potential to significantly reduce the workload of uro-pathologists and improve diagnostic quality.
Researchers are assembling the largest dataset of veterans with either condition or both to compare conditions and outcomes. They hope to find correlations between mental health and prostate cancer aggressiveness and explore biological risks like inflammation.
A new study suggests that targeted screening for men at higher genetic risk of prostate cancer could prevent nearly one in six deaths from the disease. The research modeled the harms and benefits of introducing four-yearly PSA screening for all men aged 55 to 69 versus more targeted checks for those at higher risk.
A new study published in BJU International found that short-term exercise can reduce the adverse effects of hormone therapy on cardiovascular fitness and fatigue. Patients who underwent supervised aerobic and resistance training experienced improved cardiopulmonary fitness, reduced fatigue, and enhanced quality of life.
The Milton and Carroll Petrie Department of Urology at Mount Sinai has received a $1 million grant from The Arthur M. Blank Family Foundation to fund the Prostate Cancer Program. The program aims to advance immunotherapy and personalized genomic vaccine trials aimed at treating prostate cancer.
Researchers found luteolin suppresses both early stage prostate carcinogenesis and CRPC by inducing apoptosis. MicroRNA-8080 (miR-8080) recruited by luteolin down-regulates AR-V7, inhibiting tumorigenesis and enzalutamide resistance in CRPC.
Researchers established B6CaP, a prostate-derived tumor line that frequently metastasizes to bones and grows in an immunocompetent host, overcoming limitations of previous models. This model is useful for studying mechanisms of bone metastasis and tumor immune response.
A team of researchers identified a cell surface receptor, CXCR2, essential for hormone-resistant prostate cancer cells. They showed that targeting this receptor can halt tumor growth using a drug originally intended for lung diseases.
A large study published in International Journal of Epidemiology found that being more active reduces the risk of prostate cancer. Men with a specific DNA variation associated with increased physical activity had a 51% reduced risk, suggesting overall physical activity may play a larger role than previously thought.
A clinical trial found that olaparib slowed or stopped tumour growth in men with advanced prostate cancer and BRCA mutations, with a median overall survival of 17.7 months. The study suggests that PARP inhibitors could become the first gene-targeted drug to be approved for prostate cancer.
A University of Colorado Cancer Center study suggests two new approaches to treating bone metastases from prostate cancer: targeting different signaling pathways for lytic and blastic lesions. Both types of bone metastases show promise with anti-cancer immunotherapy, particularly those with high PD-L1 levels.
A new study presents a novel MRI-guided procedure that effectively treats prostate cancer with minimal side effects. The technique, called TULSA, uses therapeutic ultrasound to destroy diseased prostate tissue while sparing healthy nerve tissue.
A new home urine test has shown to accurately diagnose aggressive prostate cancer and predict treatment needs up to five years earlier than standard clinical methods. The 'PUR' test looks at gene expression in urine samples and provides vital information about tumor aggressiveness.
A novel theranostic reagent has been developed to detect and treat metastatic prostate cancer, achieving high imaging accuracy. The reagent targets STEAP1 antigen, identifying lesions in patients with a significant number of positive results.